Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.
Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Zilli T. Achard V, et al. Among authors: berghen c. Radiother Oncol. 2022 Jul;172:1-9. doi: 10.1016/j.radonc.2022.04.020. Epub 2022 Apr 26. Radiother Oncol. 2022. PMID: 35476942 Free article. Clinical Trial.
Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial.
Draulans C, Joniau S, Fonteyne V, Delrue L, Decaestecker K, Everaerts W, Dirix P, Van den Bergh L, Crijns W, Vandendriessche H, Van Wynsberge L, Ost P, Lumen N, Buelens P, Haustermans K, Berghen C, De Meerleer G. Draulans C, et al. Among authors: berghen c. JMIR Res Protoc. 2018 Dec 13;7(12):e11256. doi: 10.2196/11256. JMIR Res Protoc. 2018. PMID: 30545809 Free PMC article.
Metastasectomy for visceral and skeletal oligorecurrent prostate cancer.
Battaglia A, Devos G, Decaestecker K, Witters M, Moris L, Van den Broeck T, Berghen C, Everaerts W, Albersen M, Tsaturyan A, De Meerleer G, Van Poppel H, Goffin K, Ost P, Tosco L, Joniau S. Battaglia A, et al. Among authors: berghen c. World J Urol. 2019 Aug;37(8):1543-1549. doi: 10.1007/s00345-019-02716-8. Epub 2019 Mar 12. World J Urol. 2019. PMID: 30859274
Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy.
Martini A, Fossati N, Karnes RJ, Boorjian SA, Boeri L, Bossi A, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Robesti D, Bartkowiak D, Böhmer D, Shariat SF, Goldner G, Battaglia A, Joniau S, Berghen C, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Martini A, et al. Among authors: berghen c. Eur Urol Oncol. 2021 Apr;4(2):301-304. doi: 10.1016/j.euo.2019.11.003. Epub 2019 Dec 4. Eur Urol Oncol. 2021. PMID: 31810893 Clinical Trial.
Salvage Radiotherapy for Prostate Cancer.
Rans K, Berghen C, Joniau S, De Meerleer G. Rans K, et al. Among authors: berghen c. Clin Oncol (R Coll Radiol). 2020 Mar;32(3):156-162. doi: 10.1016/j.clon.2020.01.003. Clin Oncol (R Coll Radiol). 2020. PMID: 32035581 Review.
Correction to: Metastasectomy for visceral and skeletal oligorecurrent prostate cancer.
Battaglia A, Devos G, Decaestecker K, Witters M, Moris L, Van den Broeck T, Berghen C, Everaerts W, Albersen M, Tsaturyan A, De Meerleer G, Van Poppel H, Goffin K, Ost P, Tosco L, Joniau S. Battaglia A, et al. Among authors: berghen c. World J Urol. 2020 Jun;38(6):1589. doi: 10.1007/s00345-020-03172-5. World J Urol. 2020. PMID: 32221712
Elective nodal radiotherapy in prostate cancer.
De Meerleer G, Berghen C, Briganti A, Vulsteke C, Murray J, Joniau S, Leliveld AM, Cozzarini C, Decaestecker K, Rans K, Fonteyne V, De Hertogh O, Bossi A. De Meerleer G, et al. Among authors: berghen c. Lancet Oncol. 2021 Aug;22(8):e348-e357. doi: 10.1016/S1470-2045(21)00242-4. Lancet Oncol. 2021. PMID: 34339655 Review.
Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
Verghote F, Poppe L, Verbeke S, Dirix P, Albersen M, De Meerleer G, Berghen C, Ost P, Villeirs G, De Visschere P, De Man K, De Maeseneer D, Rottey S, Van Praet C, Decaestecker K, Fonteyne V. Verghote F, et al. Among authors: berghen c. BMC Cancer. 2021 Oct 18;21(1):1113. doi: 10.1186/s12885-021-08861-x. BMC Cancer. 2021. PMID: 34663254 Free PMC article. Clinical Trial.
Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial.
Fonteyne V, Dirix P, Van Praet C, Berghen C, Albersen M, Junius S, Liefhooghe N, Noé L, De Meerleer G, Ost P, Villeirs G, Verbeke S, De Maeseneer D, Rammant E, Verghote F, Elhaseen E, De Man K, Decaestecker K. Fonteyne V, et al. Among authors: berghen c. Eur Urol Focus. 2022 Sep;8(5):1238-1245. doi: 10.1016/j.euf.2021.11.004. Epub 2021 Dec 8. Eur Urol Focus. 2022. PMID: 34893458 Free article. Clinical Trial.
38 results